Current management of severe acquired aplastic anemia

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Severe aplastic anemia (SAA) survival has significantly improved over four decades.
• Advances in stem cell transplantation, immunosuppressive therapies, and supportive care are key drivers.
• Horse anti-thymocyte globulin (hATG) plus cyclosporine (CsA) is the standard initial immunosuppressive therapy for SAA.

Purpose of the Study:

• To review the diagnosis and management of severe aplastic anemia.
• To evaluate the efficacy of current standard immunosuppressive therapy.
• To discuss improvements in overall survival and challenges in SAA treatment.

Main Methods:

• Review of current literature on severe aplastic anemia diagnosis and management.
• Analysis of treatment outcomes with horse anti-thymocyte globulin plus cyclosporine.
• Discussion of advances in supportive care, transplantation, and salvage therapies.

Main Results:

• Horse anti-thymocyte globulin plus cyclosporine achieves hematologic response in 60-70% of SAA patients.
• Relapse rates are 30-40%, and clonal evolution occurs in 10-15% of patients.
• Despite extensive research, no significant improvements in hematologic response rates have been achieved with alternative regimens.

Conclusions:

• Horse anti-thymocyte globulin plus cyclosporine remains the gold standard first-line immunosuppressive therapy for SAA.
• Improved survival is largely attributed to better anti-infective strategies and salvage therapies.
• Further research is needed to overcome limitations in response rates and reduce relapse and clonal evolution in SAA.